Symposium 10 Impact of innovative treatments on hematopoietic stem cell transplantations

[SY10-4] The use of Immune checkpoint inhibitor before and after allogeneic stem cell transplantation in Hodgkin lymphoma

Franck Morschhauser (Department of Hematology, University of Lille, France)

Franck Morschhauser is a Professor of Hematology and Head of the Lymphoma Unit in the Department of Hematology at the Centre Hospitalier Universitaire de Lille, in Lille, France. He is a graduate of the University of Lille, where he received his Medical degree. Dr Morschhauser serves on the Administration and Scientific Boards for LYSA (Lymphoma Study Association°. Dr Morschhauser's research interests focus on new drug development, targeted therapy, and predictive quantitative imaging for the treatment of lymphoma. He has a strong focus on translational research. He has been involved in many clinical trials. Dr Morschhauser has contributed to 106 articles published in peer reviewed journals.
Certificate of GCP training on July 5, 2017
Certificate of GCP ICH E6 (R2) training on August 8, 2017
TITLES
2013: Professor of Hematology
2008: Ph D, Nouvelles modalités (consolidation, fractionnement) de radio-immunothérapie par ⁹⁰Y-ibritumomab tiuxetan (Zevalin) en traitement de première ligne des lymphomes malin non hodgkiniens de type folliculaire : efficacité, toxicité et approche dosimétrique personnalisée. EA 1049 Médecine Nucléaire et Technologies Biomédicales, University of Lille, and Inserm UMR892, Institut de Recherche Thérapeutique University of Nantes.
2000: Associate Professor. Head of the lymphoma department, Department of Hematology, Hôpital Huriez, CHRU Lille
1996-2000: Instructor in hematology. Department of Hematology, Hôpital Huriez, CHRU Lille
1996: Post-graduate diploma in hematology
1996: Post-graduate diploma and license to practice
1996: Master degree specialized in biological and molecular science, UCL Bruxelles, Dr Martiat
1994: Master degree in immunology
1991-1996: Clinical resident, University of Lille